The concept that HH/GLI1 signaling might be required for PDAC growth, hence a suitable therapeutic target, has been first validated in a genetically engineered mouse model of pancreatic cancer that combines expression of oncogenic Kras with mutation of the tumor suppressor p53, the KPC mouse (Hingoraniet al., 2005). This evidence concerns the gene GLI1 and pancreatic neoplasm.